Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Literature DB >> 19019303

Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

Andreas J Steck¹, Adam Czaplinski, Susanne Renaud.

Abstract

This review focuses on recent data regarding inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies. We describe both acute and chronic inflammatory neuropathies, and we discuss conditions ranging from mostly cell-mediated to antibody-mediated disorders. These diseases are characterized by proximal and distal sensory motor involvement. Treatments are based on immune-modulation and/or immune-suppression. Work-up sequence and therapeutical modes are discussed in the light of recently published data, with a special interest on new treatment modalities.

Entities: Disease

Mesh：

Substances：
Glycoproteins

Year: 2008 PMID： 19019303 PMCID： PMC4514701 DOI： 10.1016/j.nurt.2008.08.012

Source DB: PubMed Journal: Neurotherapeutics ISSN： 1878-7479 Impact factor: 7.620

81 in total

1. Localization of GM1 and GD1b antigens in the human peripheral nervous system.

Authors: S Kusunoki; A Chiba; T Tai; I Kanazawa
Journal: Muscle Nerve Date: 1993-07 Impact factor: 3.217

2. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.

Authors: A Pestronk; R Choksi
Journal: Neurology Date: 1997-11 Impact factor: 9.910

Review 3. The immunobiology of Guillain-Barré syndromes.

Authors: Hugh J Willison
Journal: J Peripher Nerv Syst Date: 2005-06 Impact factor: 3.494

4. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.

Authors: Thomas H Brannagan; Armin Alaedini; Douglas E Gladstone
Journal: Muscle Nerve Date: 2006-08 Impact factor: 3.217

5. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons.

Authors: N Oka; H Kusaka; S Kusunoki; H Tsuda; R Kaji; T Imai; I Akiguchi; J Kimura
Journal: Muscle Nerve Date: 1996-04 Impact factor: 3.217

6. POEMS syndrome: definitions and long-term outcome.

Authors: Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; S Vincent Rajkumar; Terry M Therneau; Dirk R Larson; Philip R Greipp; Thomas E Witzig; Rita Basu; Guillermo A Suarez; Rafael Fonseca; John A Lust; Morie A Gertz
Journal: Blood Date: 2002-11-27 Impact factor: 22.113

7. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome.

Authors: G D Miralles; J R O'Fallon; N J Talley
Journal: N Engl J Med Date: 1992-12-31 Impact factor: 91.245

8. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab.

Authors: Anke Braun; Thomas Neumann; Peter Oelzner; Gert Hein; Hermann-Josef Gröne; Mirjana Ziemer; Gunter Wolf
Journal: Rheumatol Int Date: 2007-10-09 Impact factor: 2.631

Inflammatory demyelinating neuropathies and neuropathies associated with monoclonal gammopathies: treatment update.

1. Localization of GM1 and GD1b antigens in the human peripheral nervous system.

2. Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates.

Review 3. The immunobiology of Guillain-Barré syndromes.

4. High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy.

5. IgM M-protein with antibody activity against gangliosides with disialosyl residue in sensory neuropathy binds to sensory neurons.

6. POEMS syndrome: definitions and long-term outcome.

7. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome.

8. Cryoglobulinaemia type III with severe neuropathy and immune complex glomerulonephritis: remission after plasmapheresis and rituximab.

9. Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial.

10. Patterns of nerve conduction abnormalities in POEMS syndrome.

1. Practical considerations on the use of rituximab in autoimmune neurological disorders.

2. Update on paraneoplastic neurologic disorders.

3. Pathogenesis and Treatment of Anti-MAG Neuropathy.

Review 4. Pain management in neurocritical care.

Review 5. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.